Skip to content

Transfer Strategy in an Oocyte Donation Programme

Pilot Study of the Best Transfer Strategy in an Oocyte Donation Programme: an Intention to Treat Randomized Controlled Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03088735
Enrollment
134
Registered
2017-03-23
Start date
2017-04-05
Completion date
2019-08-31
Last updated
2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryo Transfer, Infertility, Female, Oocyte Donation

Brief summary

It has been previously shown that although the activation of the embryonic genome can begin as early as two days of initiation of the embryonic development (D2), it is expressed on day 3 (D3). Without this activation, the embryo can not continue its development. Therefore, it has been suggested that extended culture to blastocyst stage could be an option to identify and better select embryos that have been able to carry out this activation. The purpose of this study is to compare cumulative pregnancy and live birth rates following transfer of cleavage embryos or blastocysts.

Interventions

PROCEDUREBlastocyst-stage embryo transfer strategy

Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.

PROCEDURECleavage-stage embryo transfer strategy

Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients

Sponsors

Fundacion Dexeus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Patients under their first or second cycle of a synchronous (fresh) oocyte donation cycle.

Exclusion criteria

* Preimplantation genetic screening or diagnosis cycles. * Patients with strict blastocyst-stage embryo transfer indication by the couple's treating physician.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative live birth rateat 12 months after a embryo transfer (time considered enough in order to do a minimum of one frozen-thawed cycle if pregnancy is not achieved with the fresh cycleTotal number of births considering fresh and frozen thawed embryos transferred

Secondary

MeasureTime frameDescription
Cumulative pregnancy rateat 12 months after a embryo transfer (time considered enough in order to do a minimum of one frozen-thawed cycle if pregnancy is not achieved with the fresh cycleTotal number of pregnancies confirmed by ultrasound 6 weeks after embryo transfer including fresh and thawed embryos.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026